日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer

一项针对晚期非小细胞肺癌患者的tusamitamab ravtansine 1/1b期研究的生物标志物分析

期刊:Translational Oncology
影响因子:4.1
doi:10.1016/j.tranon.2025.102615
Gazzah, Anas; Ternès, Nils; Lee, Joon Sang; Wang, Emma; Carene, Dimitri; Wang, Hong; Masson, Nina; Boitier, Eric; Lartigau, Aude; Mace, Nathalie; Chadjaa, Mustapha; Dib, Colette; Nunes, Manoel; Muzard, Gaëlle; Longuemaux-Valence, Sandrine; Bauchet, Anne-Laure
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Novel Drug-Disease Modeling Framework for Oncology Benefit-Risk Evaluation: Application to Tusamitamab Ravtansine

用于肿瘤获益风险评估的新型药物-疾病建模框架：以妥沙美单抗拉坦辛为例

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.70190
Cerou, Marc; Veyrat-Follet, Christine; Fliscounakis-Huynh, Sophie; Pouzin, Clemence; Fagniez, Nathalie; Mihaljevic, Frano; Chadjaa, Mustapha; Comets, Emmanuelle; Thai, Hoai-Thu
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Development of a co-culture of Ureibacillus thermosphaericus and Cupriavidus taiwanensis for inhibitors removal from hemicellulose prehydrolysate

利用嗜热尿素杆菌和台湾贪铜菌共培养去除半纤维素预水解液中的抑制剂

期刊:Biotechnology Progress
影响因子:2.5
doi:10.1002/btpr.70107
Theiri, Mariem; Marinova, Mariya; Chadjaa, Hassan; Jolicoeur, Mario
发表日期：2026
文献求助 收藏

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5

评估 Tusamitamab Ravtansine 在癌胚抗原相关细胞黏附分子 5 高表达或中表达的非鳞状 NSCLC 患者中的安全性、药代动力学和抗肿瘤活性

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100844
Gazzah, Anas; Ricordel, Charles; Italiano, Antoine; Cho, Byoung Chul; Calvo, Emiliano; Kim, Dong-Wan; Helissey, Carole; Kim, Jin-Soo; Villar, Maria Vieito; Ghiringhelli, Francois; Moreno, Victor; Cousin, Sophie; Paz-Ares, Luis; Fagniez, Nathalie; Chadjaa, Mustapha; Bauchet, Anne-Laure; Soufflet, Christine; Masson, Nina; Barlesi, Fabrice
肿瘤
肿瘤免疫
Adhesion/ECM
CLC
细胞生物学
发表日期：2025
文献求助 收藏

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Tusamitamab Ravtansine治疗晚期实体瘤患者：采用替代给药方案的安全性、药代动力学和抗肿瘤活性I期研究

期刊:Cancer Research Communications
影响因子:3.3
doi:10.1158/2767-9764.CRC-23-0284
Tabernero, Josep; Bedard, Philippe L; Bang, Yung-Jue; Vieito, Maria; Ryu, Min-Hee; Fagniez, Nathalie; Chadjaa, Mustapha; Soufflet, Christine; Masson, Nina; Gazzah, Anas
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study

基于首次人体试验的 DM4 抗 CEACAM5 抗体药物偶联物 tusamitamab ravtansine 的协变量分析

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12769
Pouzin, Clemence; Tod, Michel; Chadjaa, Mustapha; Fagniez, Nathalie; Nguyen, Laurent
CEACAM5
发表日期：2022
文献求助 收藏

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

两项 III 期试验（FIRSTANA 和 PROSELICA）显示，转移性去势抵抗性前列腺癌患者接受紫杉烷类药物治疗后，血浆游离 DNA 浓度与疗效之间的关系

期刊:
影响因子:
doi:10.1016/j.eururo.2018.02.013
Mehra, Niven; Dolling, David; Sumanasuriya, Semini; Christova, Rossitza; Pope, Lorna; Carreira, Suzanne; Seed, George; Yuan, Wei; Goodall, Jane; Hall, Emma; Flohr, Penny; Boysen, Gunther; Bianchini, Diletta; Sartor, Oliver; Eisenberger, Mario A; Fizazi, Karim; Oudard, Stephane; Chadjaa, Mustapha; Macé, Sandrine; de Bono, Johann S
肿瘤
前列腺癌
肿瘤免疫
发表日期：2018
文献求助 收藏

Study of Separation and Fouling of Reverse Osmosis Membranes during Model Hydrolysate Solution Filtration

模拟水解液过滤过程中反渗透膜分离与污染研究

期刊:Membranes
影响因子:
doi:10.3390/membranes7040068
Olumoye Ajao, Mohamed Rahni, Mariya Marinova, Hassan Chadjaa, Oumarou Savadogo
信号转导
发表日期：2017
文献求助 收藏